What the October 2026 HHS peptide enforcement-discretion policy actually means

On 30 October 2026 the Department of Health and Human Services published a notice in the Federal Register announcing the availability of a draft “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances” (91 FR 68526, Docket HHS-OASH-2026-0496).

The notice is short. The policy document that accompanies it is longer, and the difference between what the policy does and what it is commonly described as doing is the entire story. It does not approve any peptide. It does not add anything to the 503A bulks list. It does not authorise 503B outsourcing facilities. It does not make research-use-only products lawful for human use.

What HHS actually announced

HHS states that, until each peptide is addressed in a final rule as included or not included on the 503A bulks list, it does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician that compounds a drug product using one of six peptide bulk drug substances — provided every condition in the policy is met.

The six substances are BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The policy is explicitly described as draft, interim and non-binding. HHS says it may revisit the policy if a safety signal or product-quality issue arises.

The forms and routes are part of the policy, not a footnote

Appendix B of the policy sets a specific identity and route limit for each substance. Using a different salt form, or a route outside the listed one, is outside the enforcement position. This is the detail most summaries omit.

The conditions compounders have to meet

The policy is conditional. HHS lists the circumstances that must all be present; these are the ones a reader should look for when a product is described as “covered”.

1. The bulk substance appears in Appendix A of the policy.
2. Its identity matches Appendix B, including sequence, structure, molecular weight, formula and the specified route.
3. It comes from a section 510-registered facility and is characterised in a valid certificate of analysis covering identity, purity, potency, endotoxins, heavy metals, microbial contamination and impurities.
4. The original manufacturer is registered and CGMP-compliant, and the manufacturing site is named on the certificate; repackers must have validated the manufacturer and the certificate.
5. Serious adverse events and product-quality issues are reported to FDA MedWatch and to the relevant states, and the labelling explains how to report them.
6. The label states: “This is a compounded drug product. Not for resale.”
7. The product contains only one active pharmaceutical ingredient from Appendix A.
8. For an oral dosage form, the compounder documents that the specific formulation achieves adequate human oral bioavailability.
9. The only co-packaged delivery device is an FDA 510(k)-cleared syringe.
10. The product complies with the rest of the FD&C Act, including the section 503A patient-specific prescription requirement.

Why the single-ingredient condition matters for blends

Condition 7 requires a single active ingredient. A product combining BPC-157 and TB-500 — or a four-peptide “KLOW” blend — does not meet the conditions of this policy, even if every individual peptide appears in Appendix A.

That is a direct conflict with much of the market's product design. Community-named blends are built around combining compounds; the policy is built around attributing an adverse event to one substance. A seller who describes a blend as covered by the October policy is misdescribing it.

What is still true after the policy

The six peptides remain without FDA-approved drug products. They remain unapproved for any therapeutic use. The policy does not create a lawful consumer pathway for buying lyophilised powder, and it does not convert a research chemical into a medicine.

It also does not resolve the underlying evidence question. BPC-157's human evidence remains a small retrospective series; TB-500's wound-healing literature concerns the full-length parent protein; KPV and MOTS-c remain largely preclinical. A compounding pathway changes who may make a product under conditions, not what the studies show.

• 503A compounding is patient-specific and prescription-based. It is not a retail category.
• 503B outsourcing facilities are outside the policy.
• Research-use-only labelling is outside the policy.
• The policy is interim and may be withdrawn or revised.
• Approval status is unchanged for all six substances.

What to watch next

The notice invited written comments for two weeks after publication, through Docket HHS-OASH-2026-0496 on regulations.gov — a window that closes on 13 November 2026. The next substantive steps would be FDA rulemaking on the 503A bulks list, any revision of the interim policy, and the publication of safety signals or quality findings from the reporting conditions.

Therapept will update the six compound records if the policy is revised, withdrawn, or replaced by a listing decision. Until then, each affected compound page carries a dated policy callout with the form and route limits, kept separate from the compound's approval status.